Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Delitzsch – page 49

1 023 clinical trials in Delitzsch, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Delitzsch at a glance
1 023
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 023 trials in Delitzsch

Open in trial search

Study on the Effects of Maplirpacept, Glofitamab, and Obinutuzumab in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma Not Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Pfizer Inc.

Study on the Effectiveness of Enasidenib Mesilate in Patients with Myelodysplastic Syndrome with IDH2 Mutation

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Groupe Francophone Des Myelodysplasies

Study of IMGN632, Venetoclax, and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Buparlisib and Paclitaxel for Patients with Recurrent or Metastatic Head and Neck Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Buparlisib
  • Sponsor:Adlai Nortye USA Inc.

Hodgkin's disease

Not recruiting

Study on Reducing Side Effects in Advanced Hodgkin Lymphoma Using Brentuximab Vedotin and Drug Combination for Newly Diagnosed Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:University Of Cologne

Study on Luspatercept for Patients with Lower-risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab and Golimumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Study of Imetelstat in Patients with Low or Intermediate Risk Myelodysplastic Syndromes (MDS) Refractory to Erythropoiesis-Stimulating Agents

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imetelstat Sodium
  • Sponsor:Geron Corp.

B-cell lymphoma

Not recruiting

Study on Rituximab and Drug Combination for Treating Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Abiraterone Acetate
  • Sponsor:Universitaetsklinikum Muenster AöR

Study of Ravulizumab for Children with Thrombotic Microangiopathy After Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Hodgkin's disease

Not recruiting

Study of Tislelizumab, Dacarbazine, Vinblastine Sulfate, and Doxorubicin Hydrochloride for Adults with Early-Stage Unfavorable Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:University Of Cologne

Crohn's disease

Not recruiting

Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Delitzsch

What the registry says about research in the country

01 Respiratory Diseases

Groundbreaking research focusing on severe asthma and its various manifestations, including studies evaluating new therapeutic approaches for patients with inadequate response to standard treatments.

  • Asthma exacerbation prevention
  • Eosinophilic asthma management
  • Rescue medication optimization

Multiple trials exploring innovative treatment combinations and delivery systems to improve patient outcomes.

02 Pulmonary Medicine

Comprehensive studies addressing Chronic Obstructive Pulmonary Disease, investigating advanced therapeutic options through triple therapy combinations.

  • COPD exacerbation reduction
  • Triple therapy enhancement
  • Chronic bronchitis treatment

Research aimed at improving long-term management and quality of life for COPD patients.

03 Infectious Diseases

Innovative vaccine development research targeting Cytomegalovirus (CMV) infection, with a focus on prevention strategies in high-risk populations.

  • CMV infection prevention
  • Vaccine immunogenicity
  • Primary infection protection

Trials evaluating novel mRNA-based vaccines to prevent primary CMV infection in seronegative individuals.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.